Sun Pharma Q2 profit plunges 36% on exceptional charges despite revenue growth
Excluding the exceptional items, adjusted net profit stood at ₹3,162 crore.
Account subscription benefits alongside Premium Stories, Editorials, Opinions and more.
Unlock these with Subscription
The View From India Looking at World Affairs from the Indian perspective.
First Day First Show News and reviews from the world of cinema and streaming.
Today's Cache Your download of the top 5 technology stories of the day.
Science For All The weekly newsletter from science writers takes the jargon out of science and puts the fun in!
Data Point Decoding the headlines with facts, figures, and numbers
THEdge At the cutting edge of education and careers
Health Matters Ramya Kannan writes to you on getting to good health, and staying there
Gender Agenda Stories from beyond the binary.
The Hindu On Books Books of the week, reviews, excerpts, new titles and features.
Updated - October 30, 2026 09:51 pm IST - HYDERABAD
Sun Pharmaceutical Industries reported a 36.4% year-on-year (YoY) decline in consolidated net profit to ₹1,988.5 crore for the September quarter, weighed down by exceptional charges of ₹1,268.8 crore related to its acquisition of Organon and a settlement in an antitrust litigation.
Excluding the exceptional items, adjusted net profit stood at ₹3,162 crore.
Revenue from operations, however, grew nearly 12% YoY to ₹16,198.7 crore.
“Our performance during the quarter was driven by strong momentum in India, Emerging Markets and Rest of World,” managing director Kirti Ganorkar said.
The company’s U.S. formulation sales declined 8.2% to $455 million during Q2 FY27, accounting for around 27% of its consolidated sales.
business (general) / pharmaceutical / medicine / earnings / company information
Terms & conditions | Institutional Subscriber
Comments have to be in English, and in full sentences.
They cannot be abusive or personal.
Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform.
If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles.
If you do not have an account please register and login to post comments.
Users can access their older comments by logging into their accounts on Vuukle.
Full detailed coverage is shown on the council website above. Source attribution: The Hindu – Business.
Back to all council news
